Lactic acid bacteria and
The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.
1. A method of inhibiting gram negative bacterial translocation in a mammal in need thereof, wherein:
the method comprises administering to the mammal an effective amount of bacteria selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof;
the mammal has metabolic endotoxemia; and
the mammal has a level of lipopolysaccharides that is from 2 to 4 times greater than basal lipopolysaccharide levels for such a mammal.
2. A method according to claim 1 , wherein the method comprises inhibiting translocation of gram negative bacteria to the liver and/or spleen.
3. A method according to claim 1 , wherein the method comprises inhibiting translocation of gram negative bacteria into tissue selected from mesenteric adipose tissue, subcutaneous adipose tissue, mesenteric ganglion and/or subcutaneous ganglion.
4. A method according to claim 1 , wherein the method comprises inhibiting translocation of bacteria selected from the family Enterobacteriaceae or the class Bacteroidetes.
5. A method according to claim 2 , wherein the method comprises inhibiting translocation of bacteria selected from the family Enterobacteriaceae or the class Bacteroidetes.
6. A method according to claim 3 , wherein the method comprises inhibiting translocation of bacteria selected from the family Enterobacteriaceae or the class Bacteroidetes.
7. A method according to claim 1 , wherein the administered bacteria comprises a probiotic lactic acid bacterium and/or a probiotic Bifidobacterium.
8. A method according to claim 1 , wherein the administered bacteria comprises a bacterium selected from the genera Lactobacillus, Bifidobacterium or a mixture thereof.
9. A method according to claim 8 , wherein the administered bacteria comprises Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium bifidium , or a mixture thereof.
10. A method according to claim 9 , wherein the administered bacteria comprises Lactobacillus acidophilus strain NCFM, Bifidobacterium animalis subsp. lactis strain 420, Lactobacillus salivarius strain 33, or a mixture thereof.
11. A method according to claim 1 , wherein the administered bacteria is administered in combination with one or more prebiotics.
12. A method according to claim 11 , wherein the one or more prebiotics comprise alginate, xanthan, pectin, locust bean gum, inulin, guar gum, a galacto-oligosaccharide, a fructo-oligosaccharide, polydextrose, lactitol, lactosucrose, a soybean oligosaccharide, palatinose, an isomalto-oligosaccharide, a gluco-oligosaccharide, a xylo-oligosaccharide, or a mixture of any thereof.
13. A method according to claim 12 , wherein the one or more probiotics comprise polydextrose.
14. A method according to claim 1 , wherein the mammal is a human.
15. A method according to claim 8 , wherein the mammal is a human.
16. A method according to claim 9 , wherein the mammal is a human.
17. A method according to claim 10 , wherein the mammal is a human.
18. A method according to claim 11 , wherein the mammal is a human.
19. A method according to claim 12 , wherein the mammal is a human.
20. A method according to claim 13 , wherein the mammal is a human.
21. A method according to claim 1 , wherein the mammal has bacteria of the family Enterobacteriaceae in its mesenteric adipose tissue.
22. A method according to claim 1 , wherein the mammal has bacteria of the class Bacteriodetes in its liver tissue.